CD14 and COVID-19: The contribution of miRNAs to inflammation is supported by previous data on the upregulated expression of miR-221 in mice with LPS-induced acute lung injury [63], increased levels of miR-133a-3p in atherosclerotic thrombotic cerebral infarction and cardioembolic stroke [64], and higher miR-21 content in COVID-19 patients than in non-COVID-19 volunteers [65] and its upregulation in CD14+ cells among patients with axial spondyloarthritis [66].